|
Study
|
Participants, and dose
|
Study type
|
Migraine type, age of participants
|
Outcome
|
Key results
|
Study weakness
|
|
Li et al. (2018) [14]
|
14, levetiracetam 500 mg/day
|
Open label
|
Migraine with aura and migraine without aura, 15-60 years
|
Frequency decreased, responder rate not mentioned
|
Significant
|
Small sample size, clinical efficacy not primary goal, high risk of bias
|
|
Pizza et al. (2011) [15]
|
13, levetiracetam 1000mg/day
|
Open label
|
Migraine without aura, On multiple other medication, 60-72 years
|
Frequency decreased, responder rate not mentioned
|
Significant
|
Small sample size, high risk of bias
|
|
Brighina et al. (2006) [16]
|
16, levetiracetam 1000 mg/day
|
Open label
|
Migraine with aura, 16-59 years
|
Frequency decreased, 44% completely headache free
|
Significant
|
Small sample size, high risk of bias
|
|
Gallai et al. (2003) [17]
|
19, levetiracetam 2000 mg/day (all previous non responders)
|
Open label
|
Migraine without aura, mean age 43.5 years
|
Frequency decreased, 57.9% responders
|
Significant
|
Small sample size, high risk of bias
|
|
Sadeghain et al. (2015) [18]
|
27 levetiracetam 500 mg/day, 32 Valproate 500 mg/day, 26 placebo
|
RCT
|
Migraine with aura and migraine without aura, 20-52 years
|
Frequency decreased, 63% responders
|
Significant against placebo, result not significant against Valproate
|
Small sample size
|
|
Verma et al. (2013) [19]
|
25 levetiracetam 1000mg/day, 27 placebo (failed previous prophylaxis)
|
RCT
|
Migraine with aura and migraine without aura, 17-46 years
|
Frequency decreased, 64% responders
|
Significant
|
Small sample size, high drop out rate
|
|
de Tommaso (2008) [20]
|
15 levetiracetam 1000 mg/day, 12 topiramate 100mg/day, 11 placebo
|
RCT
|
Migraine without aura, 18-49 years
|
Frequency decreased, 53.3% responders
|
Significant, result not significant against Topiramate
|
Small sample size, clinical efficacy not primary goal of study, follow up only two months
|
